Assessment of Thyroid Functions in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

EIaf Dalas, Mahdi Hamad, M. Taha
{"title":"Assessment of Thyroid Functions in Multiple Sclerosis Patients Treated with Disease Modifying Therapies","authors":"EIaf Dalas, Mahdi Hamad, M. Taha","doi":"10.47723/kcmj.v19i2.1037","DOIUrl":null,"url":null,"abstract":"Background: \nMultiple sclerosis is a chronic disease believed to be the result of autoimmune disorders of the central nervous system, characterised by inflammation, demyelination, and axonal transection, affecting primarily young adults. Disease modifying therapies have become widely used, and the rapid development of these drugs highlighted the need to update our knowledge on their short- and long-term safety profile. \nObjective: \nThe study aim is to evaluate the impact of disease-modifying treatments on thyroid functions and thyroid autoantibodies with subsequent effects on the outcome of the disease. \nMaterials and Methods: \nA retro prospective study enrolled 45 patients who were registered and diagnosed in the Multiple Sclerosis Clinic according to the revised McDonald criteria (2017). Blood samples for thyroid functions and thyroid autoantibody tests were taken before, 3 months and after 6 months from the start of disease modifying therapy. The Expanded Disability Status Scale was used to assess the severity of the disease before and after 6 months of receiving treatment. \nResults: \n45 patients with the mean age of 33.3 years, a standard deviation (SD) of ± 9.5 years were enrolled in this study. (64.4%) patients’ age was between 20 - 39 years. \nThe mean free T3 decreased significantly, while the mean anti-TPO and anti-TG increased after three months compared to its baseline level. \nAfter six months of treatment, the mean free T4 decreased significantly, while the mean TSH increased compared to its baseline level. There were no statistically significant correlations between the baseline (EDSS) score and after 6 months of therapy. \nConclusion \nThyroid hormone dysfunction and thyroid autoimmune antibody levels that changed in response to interferon beta therapy in patients with multiple sclerosis may be temporary and not associated with poor outcomes.","PeriodicalId":34748,"journal":{"name":"mjlh klyh Tb lkndy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mjlh klyh Tb lkndy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47723/kcmj.v19i2.1037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multiple sclerosis is a chronic disease believed to be the result of autoimmune disorders of the central nervous system, characterised by inflammation, demyelination, and axonal transection, affecting primarily young adults. Disease modifying therapies have become widely used, and the rapid development of these drugs highlighted the need to update our knowledge on their short- and long-term safety profile. Objective: The study aim is to evaluate the impact of disease-modifying treatments on thyroid functions and thyroid autoantibodies with subsequent effects on the outcome of the disease. Materials and Methods: A retro prospective study enrolled 45 patients who were registered and diagnosed in the Multiple Sclerosis Clinic according to the revised McDonald criteria (2017). Blood samples for thyroid functions and thyroid autoantibody tests were taken before, 3 months and after 6 months from the start of disease modifying therapy. The Expanded Disability Status Scale was used to assess the severity of the disease before and after 6 months of receiving treatment. Results: 45 patients with the mean age of 33.3 years, a standard deviation (SD) of ± 9.5 years were enrolled in this study. (64.4%) patients’ age was between 20 - 39 years. The mean free T3 decreased significantly, while the mean anti-TPO and anti-TG increased after three months compared to its baseline level. After six months of treatment, the mean free T4 decreased significantly, while the mean TSH increased compared to its baseline level. There were no statistically significant correlations between the baseline (EDSS) score and after 6 months of therapy. Conclusion Thyroid hormone dysfunction and thyroid autoimmune antibody levels that changed in response to interferon beta therapy in patients with multiple sclerosis may be temporary and not associated with poor outcomes.
接受疾病调节疗法治疗的多发性硬化症患者甲状腺功能评估
背景:多发性硬化症是一种慢性疾病,被认为是中枢神经系统自身免疫性疾病的结果,其特征是炎症、脱髓鞘和轴突横断,主要影响年轻人。疾病改良疗法已被广泛使用,这些药物的快速发展凸显了更新我们对其短期和长期安全性的认识的必要性。目的:本研究旨在评估疾病改良治疗对甲状腺功能和甲状腺自身抗体的影响,以及随后对疾病结果的影响。材料和方法:一项回顾性前瞻性研究纳入了45名根据修订的McDonald标准(2017)在多发性硬化症诊所登记和诊断的患者。在疾病改良治疗开始前、3个月和6个月后采集甲状腺功能血样和甲状腺自身抗体测试。扩展残疾状况量表用于评估接受治疗6个月前后的疾病严重程度。结果:45例患者的平均年龄为33.3岁,标准差(SD)为±9.5岁。年龄在20~39岁之间者占64.4%。与基线水平相比,平均游离T3显著下降,而平均抗TPO和抗TG在三个月后增加。治疗6个月后,与基线水平相比,平均游离T4显著下降,而平均TSH增加。基线(EDSS)评分与治疗6个月后无统计学显著相关性。结论多发性硬化症患者甲状腺激素功能障碍和甲状腺自身免疫抗体水平在干扰素β治疗后发生变化可能是暂时的,与不良预后无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
34
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信